Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20089293 | 1.00 | PLAU (0.30) | PLAU | |
| SCHEMBL20090876 | 0.75 | — | — | |
| SCHEMBL20089307 | 0.72 | — | — | |
| SCHEMBL23627302 | 0.66 | MAPK3 (0.34) | PLAU | |
| SCHEMBL31484941 | 0.66 | MAPK3 (0.34) | PLAU | |
| SCHEMBL24653595 | 0.63 | — | — | |
| SCHEMBL20089299 | 0.62 | PLAU (0.30) | PLAU | |
| SCHEMBL29623571 | 0.62 | PLAU (0.30) | PLAU | |
| SCHEMBL29029146 | 0.61 | ALDH1A1 (0.35) | — | |
| SCHEMBL16526491 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214989-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| CN-118382623-A | Naphthyridinone derivatives for use in the treatment of diseases or disorders | 诺华股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-109843887-B | Nalidinone derivatives and their use in the treatment of cardiac arrhythmias | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214989-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | PKD1, PKD2, ASAH2 | PLAU 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.